Figure - available from: Journal of Ovarian Research
This content is subject to copyright. Terms and conditions apply.
Profiling Tumor-Infiltrating Lymphocytes in ovarian cancer Mice Over Time. Tumor-infiltrating lymphocytes were harvested from ovarian cancer mice induced by ID8 cells at distinct time points following implantation and subsequently analyzed using flow cytometry. On the 10th (n = 3), 15th (n = 3), 20th (n = 3), and 25th (n = 3) days post-modeling, tumor volumes were measured. (A) The figure illustrates the frequency of TIGIT⁺ and TIGIT⁻ cells within the Foxp3⁺CD4⁺ T cell population in tumor-infiltrating lymphocytes. The r² values for TIGIT⁺ and TIGIT⁻ Tregs are 0.9258 and 0.9258, respectively. (B) The panel showcases the frequency of different subpopulations among CD8⁺ tumor-infiltrating lymphocytes expressing TIGIT and PD-1. Specifically, for CD8⁺TIGIT⁺PD-1⁺ T cells, the r² is 0.9380; for CD8⁺TIGIT⁻PD-1⁺ T cells, the r² is 0.2389, and for CD8⁺TIGIT⁻PD-1⁻ T cells, the r² is 0.4726
Source publication
Immune checkpoint-based immunotherapy has shown limited efficacy in the treatment of ovarian cancer. In recent years, the emergence of immune checkpoint co-targeting therapies, led by the combination targeting of TIGIT and FAK, has shown promise in ovarian cancer treatment. Our preliminary research indicates that TIGIT is predominantly expressed in...